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Abstract
Background: Bronchiectasis is the final result of different processes and most of the guidelines advocate for a
careful evaluation of those etiologies which might be treated or might change patients’ management, including
cystic fibrosis (CF).
Main body: CFTR mutations have been reported with higher frequency in bronchiectasis population. Although
ruling out CF is considered as a main step for etiological screening in bronchiectasis, CF testing lacks of a
standardized approach both from a research and clinical point of view. In this review a list of most widely used
tests in CF is provided.
Conclusions: Exclusion of CF is imperative for patients with bronchiectasis and CFTR testing should be
implemented in usual screening for investigating bronchiectasis etiology. Physicians taking care of bronchiectasis
patients should be aware of CFTR testing and its limitations in the adult population. Further studies on CFTR
expression in human lung and translational research might elucidate the possible role of CFTR in the pathogenesis
of bronchiectasis.
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Background
Bronchiectasis is a chronic respiratory disease character-
ized by a permanent dilation of the bronchi associated
with cough, daily sputum production and recurrent epi-
sodes of respiratory infections [1]. Although studies
probably underestimate the true prevalence of bronchi-
ectasis, recent literature suggests bronchiectasis as far
from being a rare disease [2]. Different European data-
sets describes a prevalence of bronchiectasis ranging
from 67 to 566 per 100,000 with a significant increase
with age and in females [3–5]. These records promoted
a renewed awareness of this condition as demonstrated
by an increase in research activity and the development
of international registries over the past few years [6–8].
The pathophysiology of bronchiectasis might start
with either structural airway damage or impaired muco-
ciliary clearance, leading to subsequent chronic bacterial
infection and a neutrophilic inflammation, which perpet-
uates this vicious cycle [9]. Bronchiectasis is the final re-
sult of different processes, which explains the extreme
heterogeneity of the disease [8]. The clinical spectrum of
bronchiectasis includes radiological abnormalities in al-
most asymptomatic patients as well as diffuse respiratory
involvement with severe functional and radiological im-
pairment in frequent exacerbations with high morbidity
and mortality. In view of the extreme variety of this con-
dition, different methods have been proposed in
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literature to cluster discrete groups of patients sharing
common clinical features, biological substrates and out-
comes [10–12]. Conflicting results have been proposed
with the above analysis and most of the scientific com-
munity argues on the implementation of this research in
clinical practice [13].
Besides clinical phenotypes, one of the imperative
steps in the management of patients with bronchiectasis
still remains the evaluation of the underlying etiologies
[14]. Most of the international guidelines advocate for a
careful evaluation of possible etiologies of bronchiectasis
especially those which might be treated or might change
patients’ management [15, 16]. The recent guidelines
published by the European Respiratory Society suggests
a minimum bundle of etiological tests to be performed
in adults with a new diagnosis of bronchiectasis, includ-
ing differential blood count, serum immunoglobulins
and testing for allergic bronchopulmonary aspergillosis
[14]. This conditional recommendation is based on very
low quality of evidence and practices to investigate bron-
chiectasis etiology are highly heterogeneous across Euro-
pean countries [17, 18]. Furthermore, a deep analysis of
bronchiectasis etiology might be limited by an extensive
and costly bundle of tests, which might be run only in
tertiary care centers [17, 18]. Finally, experts agree nei-
ther on the definition of some etiologies of bronchiec-
tasis (e.g. post-infective) nor the significance of “cause”
vs. “association” vs. “overlap” between bronchiectasis
and other diseases (e.g. COPD) [19].
Why rule out cystic fibrosis in adults with
bronchiectasis?
Although the scenario concerning the investigation of bron-
chiectasis etiology is still evolving, both clinical and scientific
communities agree on the need to rule out cystic fibrosis
(CF). CF is an autosomic recessive disease caused by at least
two mutations of a gene encoding a transmembrane chlor-
ide channel called Cystic Fibrosis Transmembrane Conduct-
ance Regulator (CFTR) involved in regulation of liquid
volume and anions on epithelial surfaces.
Ruling out CF in bronchiectasis patients is important
in view of clinical, social-economical and psychological
consequences. From a clinical perspective, CF is a sys-
temic disease with extra-respiratory manifestations,
which benefits from a specific management with a favor-
able impact on patients’ prognosis and quality of life
[20]. CF patients have access to respiratory therapies
that patients with bronchiectasis have not formal indica-
tion for and those with specific mutations might benefit
from new CFTR modulator therapies. From a
social-economical perspective, CF patients might benefit
from a tertiary-care management in specialized centers,
have access to free care in some countries or benefit
from a special legislation and proper health insurance
plans. From a psychological perspective, CF is a chronic,
life-limiting disease with implications for patients’ life
plans. CF patients have an increased risk of affected chil-
dren and might benefit from a referral to genetic
counseling.
Although the majority of patients with CF are identi-
fied by newborn screening or during childhood, late
diagnosis of adults is not infrequent [21]. However, test-
ing for CF is not included in the minimum bundle of in-
vestigations recommended by international guidelines
on the management of bronchiectasis patients and the
exclusion of CF is suggested only in the presence of spe-
cific clinical features [14]. These include early age of
symptom onset, diffuse bronchiectasis with predominant
upper lobe distribution on CT scan, early presence of
Staphylococcus aureus, Pseudomonas aeruginosa or Bur-
kholderia cepacia in respiratory cultures, upper airway
disease like polyps or chronic sinusitis, extra-respiratory
involvement such as recurrent pancreatitis and maldi-
gestion, or male infertility, see Table 1 [14, 16, 22–24].
In addition, there is no agreement across bronchiec-
tasis guidelines on which diagnostic test should be used
to exclude CF. While the majority of guidelines refers to
sweat chloride measurement and CFTR genetic analysis
as diagnostic standards, no hierarchical strategy of test-
ing is suggested. An international consensus on the pos-
sible strategy to exclude CF in adults with bronchiectasis
is still missing.
The lack of common ground in testing bronchiectasis
patients for CF has plenty of clinical and research impli-
cations. From a clinical perspective, CF testing seems to
be inadequate among bronchiectasis patients. The na-
tional British Thoracic Society bronchiectasis audit re-
ported testing for CF in 12% of the population [18],
while this percentage was even lower (5.5%) in a similar
audit performed in Italy [17].
From a research perspective, several randomized con-
trolled trials (RCTs) in bronchiectasis failed to meet
their primary end-points and one of the reason might be
because they did not account for the disease heterogen-
eity [25]. This is especially true looking at the exclusion
criteria listed in bronchiectasis RCTs over the past
15 years. Only five out of fifty-one trials excluded CF ac-
cording to either sweat test or genetic analysis, while the
majority of the RCTs reported excluding CF patients
only according to past medical history [26–30]. Someone
could speculate that some of these studies might have
included adult patients with mild or even severe CF due
to weakness in their exclusion criteria, thus increasing
heterogeneity in study population.
How to rule out CF in adults with bronchiectasis?
Nowadays, most CF cases are easily detected by new-
born screening and diagnoses occur in clinically
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asymptomatic infants [31]. On the contrary, diagnosis of
CF in adults can be challenging because of the hetero-
geneity of clinical manifestations resulting from highly
variable levels of CFTR dysfunction and differential ex-
posure to environmental factors [32]. Recently, guide-
lines for CF diagnosis have been reformulated by an
expert committee designated by the United States CF
Foundation [33]. According to this document, CF is
established when a subject shows either positive new-
born screening results or clinical manifestations consist-
ent with the disease and evidence of CFTR dysfunction.
The latter can be either sweat chloride test or CFTR
genetic analysis or CFTR electrophysiologic tests. All CF
patients should have a sweat test and CFTR gene ana-
lysis performed. CF is unlikely in the presence of a nega-
tive sweat test, but individuals with sweat chloride <
30 mmol/L, i.e. negative, may still have CF. The absence
of two CF-causing CFTR mutations does not exclude
the diagnosis of CF. If only one mutation is identified,
an extended CFTR genetic analysis may be taken into
account. In adult patients without classical CF diagnostic
criteria, a CFTR-related disorder (CFTR-RD) might be
considered. According to the last recommendations edi-
ted in 2011, a CFTR-RD is defined as a clinical entity as-
sociated with CFTR dysfunction that does not fulfill the
diagnostic criteria for CF [34]. CFTR-RD is usually re-
lated with three major clinical phenotypes: CBAVD
(congenital bilateral absence of the vas deferens) with
CFTR dysfunction, acute recurrent pancreatitis with
CFTR dysfunction and disseminated bronchiectasis with
CFTR dysfunction.
The most widely used test in clinical practice to diag-
nose CF/CFTR-RD are listed in Table 2 and reported
below in details.
Sweat test
Measurement of chloride after sweat induction via pilo-
carpine iontophoresis is the first-line test to diagnose CF
[33]. A chloride concentration above 59 mmol/L is used
to define a positive sweat test, while values between 30
and 59 mmol/L are deemed inconclusive and call for
further evaluations [33].
CFTR gene analysis
More than 2000 different mutations in CFTR gene have
been reported (http://www.genet.sickkids.on.ca/cftr/app)
and standard mutation panels contain the most common
CF-causing mutations (variable coverage depending on
Table 1 When and how rule out CF according to existing
bronchiectasis guidelines
Guidelines When How
ERS 2017 [14] Selected adults including
those with any of the
following: young adults;
upper lobe
predominance of
bronchiectasis on chest
CT; the presence of nasal
polyposis and/or chronic
rhinosinusitis; recurrent
pancreatitis; male
primary infertility and/or
malabsorption
Sweat chloride, other
biomarkers of CFTR
activity and CFTR
mutation analysis
Pulmonology
Portoguese Society,
2016 [16]
All children and selected
adults (no further
specified)
Two measurements of
sweat chloride and
CFTR mutation analysis
for
British Thoracic
Society, 2010 [22]
All children and selected
adults including those
with any of the
following: adults up to
the age of 40; age at
presentation > 40 years
and no other identified
cause; persistent
isolation of
Staphylococcus aureus in
the sputum; features of
malabsorption; male
primary infertility; upper
lobe bronchiectasis; a
history of childhood
steatorrhoea.
Two measurements of
sweat chloride and
CFTR mutation analysis
Normativa SEPAR,
2008 [23]
Selected adults Sweat chloride, nasal
potential difference,
CFTR mutation analysis
test
Thoracic Society of
Australia and New
Zealand, 2015 [24]
All children and selected
adults (no further
specified)
Sweat test
Table 2 Comparison among different tests to measure cystic fibrosis transmembrane conductance regulator (CFTR) ion channel
activity
Qualitative Quantitative Validated Clinical Research
Sweat test X X X X
CFTR gene analysis X X X X
NPD X X X X
ICM X X X X
Ratiometric sweat secretion optical test X X
Monocyte assay X X
CFTR cystic fibrosis transmembrane conductance regulator; NPD nasal potential difference; ICM intestinal current measurement
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panel composition and ethnic origin of the tested
people). Further steps like extensive sequencing of CFTR
gene and search for large deletions or insertions may be
indicated when two CF-causing mutations are not iden-
tified by a first level analysis but high clinical suspicion
still remains. The classification of CF-causing mutations
is still ongoing [33]; in this respect, the CFTR2 website,
originated from a project assessing disease liability of
CFTR mutations, is a useful but still incomplete tool, in-
cluding by November 2017 a total of 374 variants
(http://www.cftr2.org).
CFTR Electrophysiologic testing
Nasal potential difference (NPD) and intestinal current
measurement (ICM) are used when sweat tests and mu-
tation analysis are inconclusive and the clinical suspicion
persists [33, 35]. NPD is an in vivo test of CFTR func-
tionality by measuring nasal transmucosal voltage poten-
tial difference, both in basal conditions and after
exposure to different chemicals [36]. ICM is an ex vivo
test of CFTR function based on the measurement of
transepithelial ion transport in rectal biopsies [37]. Both
tests are complex to perform and interpret and are avail-
able only in highly specialized centers.
New assays
Ratiometric sweat secretion optical test is intended to
assess CFTR function in vivo by comparison of
CFTR-dependent and CFTR-independent sweat secre-
tion [38]. Present versions of the test have been able to
discriminate among controls, heterozygotes and CF
groups showing a continuum in CFTR impairment [39,
40] CFTR is detectable and is functional in human
monocytes. The analysis of cell membrane potential
changes after the administration of CFTR agonists is
lower in CFTR heterozygous carriers and absent in
monocytes isolated from CF patients [41]. Correlation
with CFTR activity in epithelia is still unclear and fur-
ther studies are necessary to understand the full poten-
tial of this approach.
Physicians taking care of bronchiectasis patients
should be aware that all the above tests might have some
limitations in the adult population [42, 43]. Sweat test
may be not conclusive and intermediate results may be
due to residual CFTR functionality as well as environ-
mental factors (e.g. climate, diet) or test variability [42].
In previous reports sweat chloride concentrations ap-
peared to gradually increase during life [43, 44]. In 2013
Traeger and colleagues described 13,782 sweat test per-
formed over 20 years in a single center and reported a
peak during middle age, followed by a decrease among
elderly subjects [45]. Furthermore, a cut-off of 30 mmol/
L for the definition of ‘CF unlikely’ is still debated be-
cause it just lies above the median values for sweat
chloride in this population, possibly resulting in a
greater number of subjects with ambiguous positive re-
sults [45]. Finally, over the last decades sweat test has
been largely used among infants, children and younger
adults, but a validation in elderly population is still
lacking.
Diagnostic accuracy of genetic analysis depends on the
testing strategy. CFTR gene panels can be designed to
be high in specificity, as they test only for CF-causing
mutations, at the cost of a relatively lower sensitivity. Se-
quencing and testing for deletion/duplication increase
sensitivity, but reduce specificity by identifying CFTR
variants of unknown clinical meaning.
NPD is affected by a very high intra-test variability and
several protocol variations and scores for interpretation
are reported among different centers [46, 47]. Further-
more, this method needs an experienced operator (hun-
dreds of tests performed), thus limiting a larger use [48].
ICM has been performed following different protocols
and, although discussed, it is not present in current diag-
nostic algorithm and criteria [33, 37]: validation and ref-
erence data have been reported [49] . Standard operating
procedures of both NPD and ICM are currently available
from European Cystic Fibrosis Society (https://www.ecf-
s.eu/ecfs_dnwg).
The new assays as ratiometric sweat secretion optical
test have not been validated yet in clinical practice and
they are currently used in translational research. Figure 1
reports a flow-chart for when and how to test CF in
people with bronchiectasis.
Implications for future research
Over the last decades, different investigators evaluated
the role of CFTR in adults with bronchiectasis. Increased
frequency of a single CF-causing mutation in azospermic
men was firstly reported by Dumur in 1990 [50]. Since
then, a number of papers have been published to investi-
gate the relationship between the presence of a single
CFTR mutation and the presence of diffuse bronchiec-
tasis, demonstrating that a CFTR heterozygous condi-
tion is more frequent in bronchiectasis patients with
normal sweat test in comparison to the general popula-
tion [51–54]. However, although a diagnosis of CF
should be pursued in reason to clinical or social implica-
tion, a further speculation on cost/benefit is now needed.
The question about how many adults with bronchiec-
tasis need to be tested in order to have a CF diagnosis
still remains unanswered. Two scenarios are possible:
patients older than 60 years old might not benefit from
CF testing in consideration of low catch rate and poor
impact on treatment and prognosis; otherwise, CF test-
ing will become cheaper in the future and CFTR screen-
ing could be considered.
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Also interesting for the discussion is the hypothesis that
even a single mutation in CFTR gene may contribute to
the development of lung disease. On this side, it has been
speculated that bronchiectasis may derive from a complex
multifactorial interaction between genetic risk factors and
environment. Other genes, so far unidentified, are likely to
interact with CFTR activity in the development of the dis-
ease; in particular, altered sodium homeostasis due to mu-
tations in ENaC channel is still poorly understood but
may play a contributive role [55, 56].
Next step in translational research could be the imple-
mentation of a lung genetic panel in bronchiectasis. The
strengths of this panel would be a careful selection of genes
based on current literature and the inclusion of all those
mutations known to be target of new genetic modifiers as
well as genes involved in lung inflammation. This approach
could lead to new treatments based on better molecular
understanding and different therapeutic targets. An individ-
ualized approach is necessary to understand the occurrence
and contribution of ion channel functional status in bron-
chiectasis with the aim to evaluate the overall functionality
of CFTR and, possibly, other ion channels. As factors not
covered by the sequencing of the coding region and the
exon/intron junctions could also influence CFTR function,
even a sophisticated mutation analysis alone might not
identify functionally relevant alterations. Recent develop-
ments in the field of stem cell research permit the collec-
tion of renewable tissue expressing CFTR and a detailed
study of its channel function in organoids derived from
minimally invasive rectal biopsies [57]. The use of respira-
tory cells derived from nasal brush can be envisioned in the
near future [58]. These approaches might permit to identify
previously undetected alteration in channel homeostasis
and unravel novel mechanism/s of disease.
Conclusions
Ruling out CF is a cornerstone in etiological screening
for patients with bronchiectasis and should be
Figure 1 When and how testing patients with bronchiectasis for CF
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implemented in usual work-up for investigating bronchi-
ectasis etiology. CFTR mutations, often with unclear
pathogenic effect, have been reported with higher fre-
quency among patients with bronchiectasis. Possibly, a
single mutation in CFTR combined with other genetic
and environmental factors might be involved in the
pathogenesis of bronchiectasis. Further studies on CFTR
expression in human lung and traslational research
might elucidate the role of CFTR in bronchiectasis.
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